Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and d...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2019-05-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/28/152/190035.full |
| _version_ | 1818601698792308736 |
|---|---|
| author | Emanuele Pontali Mario C. Raviglione Giovanni Battista Migliori |
| author_facet | Emanuele Pontali Mario C. Raviglione Giovanni Battista Migliori |
| author_sort | Emanuele Pontali |
| collection | DOAJ |
| description | Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9–10 months. The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB. |
| first_indexed | 2024-12-16T12:55:31Z |
| format | Article |
| id | doaj.art-41590667232a4c00b7565103a2ea64a0 |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-12-16T12:55:31Z |
| publishDate | 2019-05-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-41590667232a4c00b7565103a2ea64a02022-12-21T22:31:02ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172019-05-012815210.1183/16000617.0035-20190035-2019Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectivesEmanuele Pontali0Mario C. Raviglione1Giovanni Battista Migliori2 Dept of Infectious Diseases, Galliera Hospital, Genova, Italy Global Health Programme, University of Milan, Milan, Italy Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9–10 months. The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.http://err.ersjournals.com/content/28/152/190035.full |
| spellingShingle | Emanuele Pontali Mario C. Raviglione Giovanni Battista Migliori Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives European Respiratory Review |
| title | Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
| title_full | Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
| title_fullStr | Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
| title_full_unstemmed | Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
| title_short | Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives |
| title_sort | regimens to treat multidrug resistant tuberculosis past present and future perspectives |
| url | http://err.ersjournals.com/content/28/152/190035.full |
| work_keys_str_mv | AT emanuelepontali regimenstotreatmultidrugresistanttuberculosispastpresentandfutureperspectives AT mariocraviglione regimenstotreatmultidrugresistanttuberculosispastpresentandfutureperspectives AT giovannibattistamigliori regimenstotreatmultidrugresistanttuberculosispastpresentandfutureperspectives |